Trade Editas Medicine - EDIT CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.05 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023512% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.00129% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 2.03 |
| Open | 2.11 |
| 1-Year Change | -73.36% |
| Day's Range | 1.88 - 2.13 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Feb 21, 2025 | 1.89 | -0.39 | -17.11% | 2.28 | 2.35 | 1.87 |
| Feb 20, 2025 | 2.03 | -0.76 | -27.24% | 2.79 | 2.83 | 1.99 |
| Feb 19, 2025 | 3.17 | 1.36 | 75.14% | 1.81 | 3.27 | 1.75 |
| Feb 18, 2025 | 1.72 | 0.32 | 22.86% | 1.40 | 1.73 | 1.40 |
| Feb 14, 2025 | 1.35 | 0.11 | 8.87% | 1.24 | 1.46 | 1.24 |
| Feb 13, 2025 | 1.21 | 0.03 | 2.54% | 1.18 | 1.22 | 1.15 |
| Feb 12, 2025 | 1.18 | 0.05 | 4.42% | 1.13 | 1.19 | 1.13 |
| Feb 11, 2025 | 1.16 | -0.01 | -0.85% | 1.17 | 1.17 | 1.10 |
| Feb 10, 2025 | 1.18 | -0.03 | -2.48% | 1.21 | 1.24 | 1.18 |
| Feb 7, 2025 | 1.23 | -0.07 | -5.38% | 1.30 | 1.30 | 1.22 |
| Feb 6, 2025 | 1.28 | -0.09 | -6.57% | 1.37 | 1.38 | 1.28 |
| Feb 5, 2025 | 1.35 | 0.08 | 6.30% | 1.27 | 1.35 | 1.27 |
| Feb 4, 2025 | 1.26 | 0.00 | 0.00% | 1.26 | 1.30 | 1.23 |
| Feb 3, 2025 | 1.24 | 0.01 | 0.81% | 1.23 | 1.28 | 1.20 |
| Jan 31, 2025 | 1.29 | -0.08 | -5.84% | 1.37 | 1.38 | 1.27 |
| Jan 30, 2025 | 1.35 | -0.01 | -0.74% | 1.36 | 1.40 | 1.31 |
| Jan 29, 2025 | 1.32 | -0.06 | -4.35% | 1.38 | 1.42 | 1.31 |
| Jan 28, 2025 | 1.40 | 0.02 | 1.45% | 1.38 | 1.42 | 1.30 |
| Jan 27, 2025 | 1.39 | 0.07 | 5.30% | 1.32 | 1.42 | 1.30 |
| Jan 24, 2025 | 1.35 | -0.04 | -2.88% | 1.39 | 1.45 | 1.33 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Editas Medicine Company profile
Editas Medicine, Inc. operates as a clinical stage genome editing company. The company focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas. The company develops EDIT-101 for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. It also develops other therapies for eye diseases, such as Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; Retinitis Pigmentosa, a progressive form of retinal degeneration; and Herpes Simplex Virus 1 that causes lifelong infections leading to ocular and oral disease. In addition, the company develops hematopoietic stem cells for treating sickle cell disease and beta thalassemia. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; a strategic alliance and option agreement with Allergan Pharmaceuticals International Limited to discover, develop, and commercialize new gene editing medicines for a range of ocular disorders; and a strategic research collaboration and cross-licensing agreement with BlueRock Therapeutics to combine their respective genome editing and cell therapy technologies to discover, develop, and manufacture engineered cell medicines. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.| Industry: | Biotechnology & Medical Research (NEC) |
11 Hurley St
CAMBRIDGE
MASSACHUSETTS 02141-2110
US
News
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025
Ripple XRP price prediction: Third-party price target
Discover the ripple (XRP) price predictions for 2025 and beyond, with analyst price targets and CFDs trading strategies on Capital.com
15:29, 6 February 2025
Apple (AAPL) stock price forecast: third-party price target
We looked at the forecasts for Apple stock in 10 years to see where the price would likely be at that point and the challenges the company could face. Read more.
11:22, 6 February 2025
FARTCOIN price prediction: Third-party price target
Read our FARTCOIN price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:18, 29 January 2025
MELANIA coin ($MELANIA) price prediction: Third party price target
Read our MELANIA crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts.
11:33, 22 January 2025
TRUMP coin ($TRUMP) price prediction: third-party price target
Read our TRUMP crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:52, 22 January 2025
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025People also watch
Still looking for a broker you can trust?
Join the 690,000+ traders worldwide that chose to trade with Capital.com